Rx-360 An International Pharmaceutical Supply Chain Consortium
|
|
|
- William Nicholson
- 9 years ago
- Views:
Transcription
1 Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011
2 Rx-360 Members (Continuously updated list at Manufacturers (24) Abbott Amgen Amylin AstraZeneca Baxter Bayer Biogen Idec Boehringer Ingelheim BMS Cephalon Eli Lilly Forest Laboratories Roche/Genentech GSK Hospira Johnson & Johnson Mylan Inc. Merck & Co. Novartis Pfizer Sanofi-Aventis Takeda Teva Watson Suppliers (24) AMPAC Fine Chemicals LLC Arch Pharmalab (USA) Inc. Avantor Performance Materials, Inc. BASF Doe & Ingalls DSM Nutritional Products Ltd Fagron GE Healthcare Hikal Hovione ISP Labochim LifeConEx Life Technologies Corp. Merck KGaA Novozymes OSO BioPharmaceuticals Manufacturing LLC SICPA Sigma Aldrich Spectrum Chemical & Laboratory Products TempTime VWR West York Container 2
3 Rx-360 Observers (Continuously updated list at Auditors (7) PSC Biotech Corp. Regulatory Compliance Associates RMC Pharmaceutical Solutions Inc. Safis Solutions LLC SQA Services Inc. The Weaver Group, Inc. Auckerman Consulting Associations (11) APIC Bulk Pharmaceutical Task Force Clinton Health Access Initiative, Inc. Council for Responsible Nutrition European Fine Chemicals Group (EFCG) European Generic Medicines Association (EGA) IPEC Americas IPEC Europe NSD Bio Group Parenteral Drug Association (PDA) Pharmaceutical Quality Group (PQG) 3
4 Eligibility for Membership in Rx The following entities are eligible to become Members, subject to exceptions noted below: manufacturers of pharmaceutical or biotechnology finished products; suppliers of ingredients and components of pharmaceutical or biotechnology products; and suppliers of services relating to the quality or safety of the pharmaceutical or biotechnology supply chain. Exceptions: Providers of auditing services concerning the quality systems for, and quality of, pharmaceutical or biotechnology products, ingredients or components are not eligible for Rx- 360 membership. Providers of auditing services are eligible to become Observers of Rx Consultants are not eligible for Rx-360 membership. The following types of entities are eligible to become Observers of Rx-360: a governmental unit or quasi-governmental unit; a non-profit trade or professional association comprised of (a) pharmaceutical or biotechnology manufacturers, (b) suppliers of pharmaceutical/biotechnology ingredients or components, (c) suppliers of services relating to the quality or safety of the pharmaceutical or biotechnology supply chain, and/or (d) individuals employed by or whose activities relate to the pharmaceutical or biotechnology industries; and auditors of the quality systems for, and quality of, pharmaceutical or biotechnology products, ingredients or components. 4
5 How to Become a Member For Manufacturers and Suppliers: Review the Rx-360Antitrust/Anticompetitive Policy Review the Rx-360Bylaws. Sign and submit Membership Agreement to Rx-360 Secretariat For Observers Review the Rx-360Antitrust/Anticompetitive Policy Review the Rx-360Bylaws. Sign and submit Observer Agreement to Rx-360 Secretariat 5
6 By-laws and Agreements -- General Rx-360 By-laws Membership Agreement Observer Agreement Anti-trust/Anti-competitive Policy 6
7 Agreements for Participation in Audit Sharing Program Accessed through Rx-360 Database Membership Supplemental Confidentiality Agreement Between pharmaceutical manufacturer member or supplier member and Rx-360 Confidential Disclosure Agreement (CDA) Concerning Audit by Individual Rx-360 Member Between supplier and Rx-360 7
8 Agreements for Participation in Audit Sharing Program (Diagram) Pharma and Suppliers (Rx-360 Members) Suppliers (Rx-360 Members and Non-members) Membership Supplemental Confidentiality Agreement CDA for Audit by Individual Rx-360 Member Rx-360 Secretariat 8
9 Audit Sharing Concept Share reports and responses from audits conducted by individual member companies (not by Rx-360) Companies decide individually how to use information in the audit reports/responses Suppliers can exclude specific companies (i.e., competitors) from viewing the audit reports/responses Suppliers can also vet new members joining Rx-360 who have requested access to a Shared audit report 9 9
10 Benefits of Sharing Audit Reports for Sponsors and Suppliers Leveraging Information Already Available Provides a Broader Picture of Quality Culture and Performance Potential for Reducing Frequency and/or Length of Audits (Routine/Due Diligence) Identify and Pre-screen New Suppliers Promote Capabilities to Consortium Competitive Advantage and Visibility to Potential Customers 10
11 Audit Sharing Process: Overview Sponsor & Supplier agree to share audit report/responses Sponsor & Supplier Redact reports/responses Rx-360 uploads reports/responses into database (documents controlled by CDAs) 11
12 Audit Sharing Process: Detail (Scope and process described in further detail in Rx-360 SOPs) Plan to Share Audit Agree to Share Audit Report (and Responses) Redact Audit Report (and Responses) Share Audit Report (and Responses) Sponsors sign CDA Sponsors identify and contact suppliers that they will audit during the year Sponsors inform suppliers of the audit sharing program and ask them to participate Sponsors register suppliers in database Supplier reviews audit sharing information and speaks with Sponsor and/or Coordinator Supplier agrees to share audit report and responses (this can be done prior to or after the audit report is issued) Supplier signs CDA and identifies Rx-360 member companies that are allowed access to report/responses Sponsor redacts audit report and sends to supplier Supplier redacts audit report (if needed) and sends to Coordinator Coordinator uploads audit report into database 12 12
13 Rx-360 Database (1) Accessible to Rx-360 members Managed according to a Database Protocol describing, e.g., Change management (for the database) Security Disaster recovery Naming conventions Two main sections: Consortium internal documents (e.g, minutes, slides) Shared and Join Audit Program materials 13
14 Rx-360 Database (2) Shared Audit Program Materials Quality Management System (Quality Manual) Audit Reports and Responses Shared Audits Standard Operating Procedures (SOPs) Database protocol Signed Agreements Membership Suppliers 14
15 Quality Management System (QMS) Accessed through Rx-360 database Describes the Rx-360 Quality Policy Describes the Rx-360 Code of Ethics Describes policies for Developing Rx-360 procedures Governance Roles and responsibilities Audit processes Integrates and describes the Audit Sharing and Joint Audits goals and processes Describes key aspects and purpose of database Describes document management Describes and refers to forms, templates, SOPs, protocols, and agreements relevant to audit programs 15
Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency
Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency www.rx-360.org www.rx-360.org Presenter: Rob Welsh, VWR International, LLC VP Category Management
CHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct
Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:
Pharma working capital leaves room for improvement
October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.
In the largest and perhaps the most ambitious collaborative
FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated
Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)
A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors
Pharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors
Multiple Sclerosis Treatments: World Market Outlook to 2011
Brochure More information from http://www.researchandmarkets.com/reports/2860814/ Multiple Sclerosis Treatments: World Market Outlook to 2011 Description: Multiple sclerosis (MS) is a chronic demyelinating
e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015
e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017
ehealthinsight Series: Online Patient Recruitment Strategies
A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments
Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for
Biotechnology in North Carolina
Biotechnology in North Carolina UNC-DoD Roundtable Bio-supported Products and Systems for the National Defense September 16, 2004 Kenneth R. Tindall, Ph.D. Sr. V. P. for Science and Business Development
1) SCOPE OF THE PROGRAM
CALL FOR PROJECTS 2015/16 CANADA/GERMANY JOINT PROGRAM DEADLINE: 15 TH JANUARY 2016 1) SCOPE OF THE PROGRAM The main goal of the Canada/Germany joint program is to strengthen research in Canada and Germany
THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS
THE GABOR DANIELFY SCHOLARSHIP FOR HEALTHCARE COMPLIANCE & ETHICS I. Mission: Seton Hall Law School, Sciences Po, and ETHICS - the International Society of Healthcare Ethics and Compliance Professionals,
How companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS
INTERNATIONAL PHARMACEUTICAL PRIVACY CONSORTIUM COMMENTS IN RESPONSE TO THE CALL FOR EVIDENCE ON EU DATA PROTECTION PROPOSALS I. INTRODUCTION The International Pharmaceutical Privacy Consortium (IPPC)
THE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
Manufacturer of drug substance
Original s and Biosimilars (marketing authorizations in the EU) Date: January 2016 1) Somatropin s ORIGINAL PRODUCTS: Authorization Genentech Genotropin Somatropin Pharmacia/ Pfizer E. coli Humatrope Somatropin
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
To know more about Pharmacovigilance and Clinical Trials Data Management
To know more about Pharmacovigilance and Clinical Trials Data Management 1. What is Pharmacovigilance? Pharmacovigilance (PV) is the pharmacological science related to the detection, assessment, understanding
Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global
Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar [email protected]
Annual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
Rx-360 Supply Chain Security White Paper: Incident Management
Rx-360 Supply Chain Security White Paper: Incident Management 1 Contents Background... 3 Scope... 3 Definitions... 4 Introduction... 5 Discovery & Investigation... 5 Incident Management... 6 Lessons Learned...
Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)
Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the
Pharmaceutical Quality Systems (ICH Q10) Conference. Business Case for Quality
Pharmaceutical Quality Systems (ICH Q10) Conference Business Case for Quality Jeffrey Macher, PhD Associate Professor McDonough School of Business Georgetown University Presentation Agenda Business Case
Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion
Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011
Pharmaceutical Distribution in the US: Current and Future Perspectives
Pharmaceutical Distribution in the US: Current and Future Perspectives Publication date: July 2009 Number of pages: 83 Author: Dr Faiz Kermani Pricing: 1,495 (PDF) / 1,550 (print) "In the US, the pharmaceutical
PHARMACEUTICAL INDUSTRY PROFILE
PHARMACEUTICAL INDUSTRY PROFILE I. INDUSTRY BACKGROUND A. Industry Definition The U.S. pharmaceutical industry is defined by the Census Bureau as companies engaged in researching, developing, manufacturing,
Tuas Biomedical Park
Tuas Biomedical Park About Tuas Biomedical Park Tuas Biomedical Park symbolises JTC s commitment in developing a world-class manufacturing hub for the biomedical industry. The park is located in Tuas View,
GMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage
CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS
CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS Adopted November 2013, in force since 1 st of January 2014. INTRODUCTION The Association
Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013
Brochure More information from http://www.researchandmarkets.com/reports/2599260/ Top ICT spenders in the US Pharmaceutical Industry - Estimated ICT budget breakdowns in 2013 Description: Synopsis This
TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet
TransCelerate's Role in Transforming Pharmaceutical Trials Presentation to PCORNet Dalvir Gill, PhD - Chief Executive Officer 17 October, 2014 Presentation Objectives + TransCelerate History + Participating
Identity Management & Digital Signatures in the BioPharmaceutical Industry John Hendrix; Program Director CTST 2009
Identity Management & Digital Signatures in the BioPharmaceutical Industry John Hendrix; Program Director CTST 2009 2009 SAFE-BioPharma Association Overview Conducting Business in the Electronic World
INCENTIVE COMPENSATION CONFERENCE
Announcing the 2nd Annual ZS Associates INCENTIVE COMPENSATION CONFERENCE 08 September 23 24, 2008 Philadelphia, PA Incentive compensation greatly affects sales force motivation and morale. When designed
Christopher Kratochvil, MD, Assistant Vice Chancellor for Clinical Research Deborah Vetter, MS, Director, Sponsored Programs Administration
Christopher Kratochvil, MD, Assistant Vice Chancellor for Clinical Research Deborah Vetter, MS, Director, Sponsored Programs Administration Clinical Research Center Learn-At-Lunch Series October 13, 2011
CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW
CONTRACT RESEARCH ORGANIZATION INDUSTRY OVERVIEW April 2014 Investment banking services are provided by Harris Williams LLC, a registered broker-dealer and member of FINRA and SIPC, and Harris Williams
Commercial Insight Osteoarthritis and Rheumatoid Arthritis
A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and
CALCET Company California Consulting Engineering & Technology 14895 E14th St. Ste 340, San Leandro, CA 94578 USA www.calcet.com
CALCET Company California Consulting Engineering & Technology 14895 E14th St. Ste 340, San Leandro, CA 94578 USA www.calcet.com ENGINEERING A PIVOTAL ROLE IN BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES
Published by Waterford Life Sciences, Washington, DC 202-299-0600 Cover and book design: Gretchen Maxwell, GLM Design
Copyright 2007 Scott M. Fishman, MD CME Activity Copyright 2009 The University of Wisconsin Board of Regents Published by Waterford Life Sciences, Washington, DC 202-299-0600 Cover and book design: Gretchen
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries
Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be
Metastatic Breast Cancer - Pipeline Review, Q1 2011
Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary
Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
Pharmaceutical Marketing Disclosures
Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,
Stakeholder Perspectives: Mild Cognitive Impairment and Dementia
A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?
APV/IPEC Europe Excipient Conference 2014
APV/IPEC Europe Excipient Conference 2014 An update on regulatory and application developments 23 to 24 September 2014 Düsseldorf, Germany Course No. 3128 Marketing Düsseldorf Target Group This conference
EU Clinical Trials Register
EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 [email protected]
Health Care Job Information Sheet #20. Clinical Research
Health Care Job Information Sheet #20 Clinical Research A. Background B. Occupations 1) Clinical Research Associate (Study Monitor) 2) Clinical Research Coordinator 3) Other positions in the field C. Labour
KEEPING CLINICAL TRIALS IN AUSTRALIA
OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought
Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions
Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions Philip S. Brewster Brewster Law Firm LLC July 29, 2014 Schering Charitable
Accelerating Drug & Clinical Trial Approvals in China & East Asia
25 28 March 2014 The Westin Beijing Chaoyang, Accelerating Drug & Clinical Trial Approvals in & East Asia What s New in 2014? Key Regulatory Update from the National Institute for Food & Drug Control,
Global Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
Main Conference Agenda
Sponsored by: (Co-located with Bioequivalence: Intersection between Science & Regulatory Conference) Main Conference Agenda Day One Wednesday, November 5 th, 2014 7:30 Registration Opens & Continental
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight
CONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services.
CONCEPT HEIDELBERG Pharmaceutical Quality Training. Conferences. Services. About Us Helping you to Comply with GMP Since our foundation on 1 April 1978, CONCEPT HEIDELBERG has been concentrating on providing
Roots Analysis Pvt. Ltd.
Roots Analysis Pvt. Ltd. http://www.marketresearch.com/rootsanalysispvt.ltd. -v3981/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am
Black Mountain Consulting Group. Not just Knowledge..Know-How
Black Mountain Consulting Group Not just Knowledge..Know-How BMCG in a Nutshell. A collaborative of more than 45 Pharmaceutical Industry experts, each with more than 10 years of success in their well defined
Medical Writing Takes Off in India
Visit http://store.centerwatch.com to learn more about State of the Clinical Trials Industry 2008 Special Article Reprint For the latest news and views on the clinical trials industry visit ClinicalTrialsToday.com
van den Besselaar Mobile Phone no. : +31(0) 653796401 E-mail: [email protected]
Resume/CV Leo van den Besselaar Personal Details Title Ing. Male Surname or family name van den Besselaar First or given name Leo (Leonardus Adrianus Maria) Nationality Dutch Date of Birth June 12, 1963
The United States False Claims Act Qui Tam Whistleblower Law
The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP Counsellors At Law Rockefeller Center, 620 Fifth Avenue New York, NY 10020 Phone: (212) 376-5666 Fax: (212) 292 3942 www.getnicklaw.com
Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis
Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation
How To Schedule A Lab
Online Exclusive from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE September/October 2012, Vol. 32 No. 5 www.pharmaceuticalengineering.org Copyright ISPE 2012 This article presents the various
Pharmaceutical industry
8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and
Peter Erickson. C2 Healthcare CREATIVE DIRECTOR/COPY/CONTENT. Chicago. Creative Director/Senior Copywriter/Content Strategist
Peter Erickson CREATIVE DIRECTOR/COPY/CONTENT Chicago Leading, inspiring, innovating. [email protected] 630.253.5199 mobile Challenges drive most of us creative professionals. As a creative director,
Resource Scheduling in QC Laboratories
Reprinted from PHARMACEUTICAL ENGINEERING The Official Technical Magazine of ISPE November/December 2012, Vol 32, No 6 Copyright ISPE 2012 www.pharmaceuticalengineering.org quality systems in QC Laboratories
Amgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers and temporary staff worldwide ( Covered Persons ). Consultants, contract workers,
GAMP5 - a lifecycle management framework for customized bioprocess solutions
GE Healthcare Life Sciences GAMP5 - a lifecycle management framework for customized bioprocess solutions imagination at work GE Healthcare s engineering department, Customized Bioprocess Solutions (CBS),
New Jersey Bio-Pharmaceutical Life Sciences Landscape
New Jersey Bio-Pharmaceutical Life Sciences Landscape Prepared By: John Ehret Labor Market Analyst New Jersey Department of Labor & Workforce Development Division of Labor Market & Demographic Research
from PKI to Identity Assurance
from PKI to Identity Assurance Richard Trevorah Technical Manager tscheme Ltd Tel: +44 (0)7818 094728 [email protected] What is tscheme? tscheme is a not-for-profit membership organisation chartered
Biopharmaceutical Raw Materials throughout the Product Lifecycle
February 27 March 2, 2012 Hilton San Diego Bayfront San Diego, CA Monday Tuesday Programming: IBC s 17th International Process & Analytical Assay Validation IBC s 8th International Outsourcing Manufacturing
The Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs
Roopa Ramamoorthi PhD, PMP, Associate Director, Partnering and Scientific Affairs BIO Ventures for Global Health Sharing Innovation in the Fight Against Neglected Tropical Diseases World Intellectual Property
PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management
PG Diploma in Clinical Research, Pharmacovigilance, Regulatory and Clinical Data Management Contact: +91 9886735658, 080 28411665 ext 5103 Email: [email protected] PG Diploma In Clinical Research,
PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM
PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM April 2013 Executive Summary Ontario Regulation 298/12 "Collection of Pharmaceuticals and Sharps - Responsibility of Producers" came into force on
An integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
Services Providers. Ivan Soto
SOP s for Managing Application Services Providers Ivan Soto Learning Objectives At the end of this session we will have covered: Types of Managed Services Outsourcing process Quality expectations for Managed
Great Expectations: Enhanced Obligations in Recent HHS-OIG Corporate Integrity Agreements
Thomas W. Beimers Special Counsel Faegre Baker Daniels LLP Minneapolis MN Great Expectations: Enhanced Obligations in Recent HHS-OIG Corporate Integrity Agreements The Department of Health & Human Services,
Source: BIO, Factset, NASDAQ
Inside The NBI A guide to performance drivers of the NASDAQ Biotech Index Introduction The NASDAQ Biotechnology Index (NBI) is referenced by investors, CEOs, and industry leaders around the world to take
Document and Quality Management Solutions for Life Sciences
Document and Quality Management Solutions for Life Sciences Company Overview Global Provider Established US and European footprint Proven Solution SharePoint based document and quality management. Solutions
ABCD. Welcome to BICI. Petersburg, Virginia
Welcome to BICI Petersburg, Virginia Our Company Our Worldwide Company in Brief: - Focus on Human Pharmaceuticals and Animal Health - Founded 1885 in Ingelheim, Germany - Products marketed in some 150
